Morgan Stanley's initiation of coverage on Marsh & McLennan with an Equal-Weight rating and a price target of $202 indicates a neutral outlook for the stock. This news is important for investors as it provides an expert opinion on the stock's valuation. However, the Equal-Weight rating suggests that the stock is expected to perform in line with the market, which implies a neutral short-term price impact.